Scholarlink

<p>Physiologically based pharmacokinetic (PBPK) modeling has emerged as a valuable tool in model-informed drug development (MIDD). This approach enables the integration of diverse experimental data to predict pharmacokinetics (PK) and dosing regimens and facilitates understanding of mechanism of action (MoA) and pharmacodynamics (PD). In this article we provide a landscape analysis of PBPK submissions at the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). We summarize CBER's experience on PBPK modeling and simulation (M&amp;S) for therapeutic proteins, cell and gene therapy products. We discuss specific case studies that illustrate the use of PBPK for dose selection of therapeutic proteins, highlight recent progress and provide our perspectives on potential application of PBPK for adeno-associated virus (AAV)-based gene therapies and messenger RNA (mRNA) therapeutics. For cell and gene therapy products, PBPK M&amp;S is emerging as MIDD approaches to support clinical trial design, dose selection, predicting PK/PD, and facilitate quantitative understanding of safety and efficacy. As the field continues to evolve, PBPK modeling is well positioned to provide supportive evidence to facilitate the development of safe and effective biological products.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Physiologically Based Pharmacokinetic Modeling and Simulation in Regulatory Review: US FDA CBER Experience and Perspectives

  • 期刊论文

  • 发表日期：

    2025年10月9日

查看全文
  • Million A. Tegenge,
  • Osman N. Yogurtcu,
  • Artur A. Belov,
  • Xiaofei Wang,
  • Richard A. Forshee

摘要

Physiologically based pharmacokinetic (PBPK) modeling has emerged as a valuable tool in model-informed drug development (MIDD). This approach enables the integration of diverse experimental data to predict pharmacokinetics (PK) and dosing regimens and facilitates understanding of mechanism of action (MoA) and pharmacodynamics (PD). In this article we provide a landscape analysis of PBPK submissions at the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER). We summarize CBER's experience on PBPK modeling and simulation (M&S) for therapeutic proteins, cell and gene therapy products. We discuss specific case studies that illustrate the use of PBPK for dose selection of therapeutic proteins, highlight recent progress and provide our perspectives on potential application of PBPK for adeno-associated virus (AAV)-based gene therapies and messenger RNA (mRNA) therapeutics. For cell and gene therapy products, PBPK M&S is emerging as MIDD approaches to support clinical trial design, dose selection, predicting PK/PD, and facilitate quantitative understanding of safety and efficacy. As the field continues to evolve, PBPK modeling is well positioned to provide supportive evidence to facilitate the development of safe and effective biological products.